Triamcinolone Acetonide Injection Shortage

Source: FDA · United States

Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

FDA lists a current shortage of Triamcinolone Acetonide Injection (TRIESENCE) for ophthalmology use.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on August 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.

It is tempting to skim, check personal relevance, and move on. The better habit is confirming scope, source, and timestamp first, then reading this alongside related notices instead of drawing a conclusion from one record alone.

The original agency source is linked below so you can verify this record directly before acting on it. Its related labels are drug-shortage, fda, medication, Triamcinolone Acetonide.

What's in Shortage

Triamcinolone Acetonide Injection (brand name: TRIESENCE), dosage form Injection, therapeutic category Ophthalmology. Shortage status is Current. First posted 09/27/2021, last updated 07/23/2026.

Which Manufacturers Are Affected

  • Harrow Eye, LLC: Available. Presentation: Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01). Contact: (615) 733-4734.

Why There's a Shortage

No specific reason was provided in the source data.

What Patients Should Do

Patients should talk to their pharmacist, ask about alternatives if needed, and contact the manufacturer for the most current information. Always consult your healthcare provider before making any changes to your medication.

Source

FDA Drug Shortage Database

Original source: FDA Official Notice ↗

All Drug Shortages →

Comparable nationwide notices (length or severity timing) 8

Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

What People Ask

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about? ▾
FDA lists a current shortage of Triamcinolone Acetonide Injection (TRIESENCE) for ophthalmology use.
Which agency issued this alert? ▾
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert? ▾
This alert is classified as "medium" severity. Stay informed and follow agency guidance.
What area is affected? ▾
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates? ▾
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.